MIRA vs NRXP vs AXSM vs ATAI vs JAZZ

For growth investors, Axsome Therapeutics, Inc.

(AXSM) is the stronger pick with 65. 5% revenue growth year-over-year, versus -1. 9% for Atai Beckley N. V (ATAI). Analysts rate Axsome Therapeutics, Inc. (AXSM) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Axsome Therapeutics, Inc.

(AXSM) delivered a total return of +286. 4%, compared to -99. 1% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: AXSM returned +1886% versus NRXP's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Jazz Pharmaceuticals plc (JAZZ) is the lower-risk stock at 0.

65β versus NRx Pharmaceuticals, Inc. 's 1. 91β — meaning NRXP is approximately 195% more volatile than JAZZ relative to the S&P 500. On balance sheet safety, Atai Beckley N. V (ATAI) carries a lower debt/equity ratio of 21% versus 3% for Axsome Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Axsome Therapeutics, Inc.

(AXSM) is pulling ahead at 65. 5% versus -1. 9% for Atai Beckley N. V (ATAI). On earnings-per-share growth, the picture is similar: NRx Pharmaceuticals, Inc. grew EPS 43. 9% year-over-year, compared to -272. 0% for Atai Beckley N. V. Over a 3-year CAGR, AXSM leads at 133. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MIRA Pharmaceuticals, Inc.

(MIRA) is the more profitable company, earning 0. 0% net margin versus -484. 6% for Atai Beckley N. V — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JAZZ leads at 5. 3% versus -333. 4% for ATAI. At the gross margin level — before operating expenses — ATAI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ATAI: 199.

3% to $12. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Axsome Therapeutics, Inc.

(AXSM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 69), +1886% 10Y return). NRx Pharmaceuticals, Inc. (NRXP) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AXSM: +1886%, NRXP: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MIRA is a small-cap quality compounder stock; NRXP is a small-cap quality compounder stock; AXSM is a mid-cap high-growth stock; ATAI is a small-cap quality compounder stock; JAZZ is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.